Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.31 |
| ▸ | MEN1 | O00255 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 3/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17211817 | 0.91 | DGAT1 (0.35) | MAPTLMNASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL17211807 | 0.84 | ALDH1A1 (0.33) | MAPTALDH1A1GAA | |
| SCHEMBL17211811 | 0.82 | ALDH1A1 (0.31) | MAPTSMN1; SMN2ALDH1A1GAA | |
| SCHEMBL17211801 | 0.75 | SMN1; SMN2 (0.43) | MAPTLMNASMN1; SMN2ALDH1A1HTT | |
| SCHEMBL17211809 | 0.74 | ALDH1A1 (0.31) | MAPTALDH1A1GAA | |
| SCHEMBL17211803 | 0.73 | TDP2 (0.44) | MAPTMEN1LMNAKMT2AMAPK1 | |
| SCHEMBL10341539 | 0.72 | SMN1; SMN2 (0.47) | LMNASMN1; SMN2ALDH1A1GAA | |
| SCHEMBL17211815 | 0.70 | ALDH1A1 (0.35) | MAPTSMN1; SMN2ALDH1A1GAA | |
| SCHEMBL17460906 | 0.70 | DGAT1 (0.40) | MAPTMEN1LMNAKMT2ASMN1; SMN2 | |
| SCHEMBL17211802 | 0.69 | ESR2 (0.34) | MAPTMEN1KMT2AHTTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242929-B2 | Compounds as diacylglycerol acyltransferase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-01-26 | — | — | US | disclosed |
| US-20150307445-A1 | Novel Compounds as Diacylglycerol Acyltransferase Inhibitors | GlaxoSmith Kline Intellectual Property (No.2) Limited (GB) | 2015-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307445-A1 | Novel Compounds as Diacylglycerol Acyltransferase Inhibitors | DGAT1, DGAT2, LCAT | MAPT 1704/4885MEN1 4075/4885LMNA 3751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.